# Efficacy and Safety of 1612 Capsules in aMnestic Mild Cognitive Impairment

> **NCT02982642** · PHASE4 · WITHDRAWN · sponsor: **Dongzhimen Hospital, Beijing**

## Conditions studied

- Mild Cognitive Impairment

## Interventions

- **DRUG:** 1612 capsule
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT02982642
- **Lead sponsor:** Dongzhimen Hospital, Beijing
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-01
- **Primary completion:** 2018-12
- **Final completion:** 2018-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor cannot conduct research due to insufficient funding supportment
- **Last updated:** 2021-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02982642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02982642, "Efficacy and Safety of 1612 Capsules in aMnestic Mild Cognitive Impairment". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT02982642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*